Pfizer Gets FDA Nod, Best Buy Drops iPhone 5C Price, and 3 More Hot Stocks

Pfizer Inc. (NYSE:PFE): The Food and Drug Administration has given Pfizer’sĀ Duavee drug for the treatment of moderate to severe hot flashes and post-menopausal osteoporosis the go-ahead. It will now go up against Eli Lilly’sĀ Evista, which generated $1 billion in sales last year. “Duavee contains the ingredient bazedoxifene that can act like estrogen on bone to protect density combined with a mixture of estrogens,” Bloomberg reports.

F 20131004